Faculty Collaboration Database

Probabilistic cost-effectiveness analysis of HIV prevention. Comparing a Bayesian approach with traditional deterministic sensitivity analysis. Eval Rev 2001 Aug;25(4):474-502

Date

08/02/2001

Pubmed ID

11480309

DOI

10.1177/0193841X0102500404

Scopus ID

2-s2.0-0035432898 (requires institutional sign-in at Scopus site)   5 Citations

Abstract

In cost-effectiveness analysis, the incremental cost-effectiveness ratio is used to measure economic efficiency of a new intervention, relative to an existing one. However, costs and effects are seldom known with certainty. Uncertainty arises from two main sources: uncertainty regarding correct values of intervention-related parameters and uncertainty associated with sampling variation. Recently, attention has focused on Bayesian techniques for quantifying uncertainty. We computed the Bayesian-based 95% credible interval estimates of the incremental cost-effectiveness ratio of several related HIV prevention interventions and compared these results with univariate sensitivity analyses. The conclusions were comparable, even though the probabilistic technique provided additional information.

Author List

Johnson-Masotti AP, Laud PW, Hoffmann RG, Hayat MJ, Pinkerton SD

Author

Purushottam W. Laud PhD Professor in the Institute for Health and Equity department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Bayes Theorem
Cost-Benefit Analysis
Female
HIV Infections
Humans
Male
Probability
Quality-Adjusted Life Years
Sexual Behavior